Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group

[1]  T. Powles,et al.  Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers , 2023, The Lancet.

[2]  G. Nesi,et al.  Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope? , 2023, International journal of molecular sciences.

[3]  B. Rini,et al.  Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial , 2022, The Lancet.

[4]  Fernando Maciel Barbosa,et al.  Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2022, The Lancet. Oncology.

[5]  Xi Zhang,et al.  Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer. , 2022, Clinical nutrition.

[6]  Kazuhiko Yoshida,et al.  Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma. , 2021, Clinical genitourinary cancer.

[7]  T. Laajala,et al.  A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma , 2021, Scientific Reports.

[8]  I. Derweesh,et al.  Preoperative Elevation of C-Reactive Protein Is a Predictor for Adverse Oncologic Survival Outcomes for Renal Cell Carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC). , 2021, Clinical genitourinary cancer.

[9]  S. Kaasa,et al.  An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer , 2019, Medicine.

[10]  K. Thomas,et al.  Surgery for high‐risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International Metastatic Renal Cell Cancer Database Consortium (IMDC) score , 2019, BJU international.

[11]  S. Niemczyk,et al.  Neutrophil‐to‐lymphocyte Ratio, Platelet‐to‐lymphocyte Ratio, and C‐reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta‐analysis , 2018, Clinical genitourinary cancer.

[12]  William P. Parker,et al.  Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. , 2018, European urology.

[13]  R. Motzer,et al.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Davies,et al.  Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. , 2017, Journal of vascular surgery. Venous and lymphatic disorders.

[15]  Shenglin Ma,et al.  Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients , 2017, World Journal of Urology.

[16]  J. Patard,et al.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.

[17]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[18]  U. Harmenberg,et al.  Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study , 2016, World Journal of Urology.

[19]  C. Porta,et al.  Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy , 2015, Targeted Oncology.

[20]  S. Urakami,et al.  Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors , 2013, International Journal of Clinical Oncology.

[21]  Y. Tomita,et al.  Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. , 2010, European urology.

[22]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Patard,et al.  Multi-institutional validation of a new renal cancer-specific survival nomogram. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Patard,et al.  A preoperative clinical prognostic model for non‐metastatic renal cell carcinoma , 2003, BJU international.

[25]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[26]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[27]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[28]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Patard,et al.  Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. , 2018, European urology.

[30]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.